All-cause mortality during follow-up showed a trend towards statistically significant difference across the groups ( p = 0.053), with the highest proportion of deaths occurring in the LL group (51.4%) compared to the HH (29.3%) and VAR (30.5%) groups.
ETS‐18S pre‐rRNA was only increased in the ACT trial at 24 h ( P = 0.004), and it showed a trend to be higher compared to CWI trial at the same time point ( P = 0.053) (Fig. 4 D).
However, total cholesterol showed a trend towards a decrease in the EG ( p = 0.053) and a significant increase in the CG ( P = 0.015).
In our cohort, PDAC showed a trend toward lower CR-POPF rates compared to non-PDAC cases (29.1 % vs. 44.0 %, p = 0.053), although this did not reach significance in multivariable analysis ( p = 0.722).
A direct comparison of the two active patterns (Additional file 1: Table S4) indicated comparable risks for most outcomes, except for myocardial infarction, where concentrated activity showed a trend toward a higher risk (HR 1.19, 95% CI 1.00–1.42, P = 0.053).
Strawberry-flavored stimuli ratings were not significantly different from savoury-flavored stimuli, but showed a trend towards higher ratings for strawberry (p = 0.053).
Glucose levels showed a trend toward correlation with age ( r = 0.22, p = 0.053; Figure 2c ) but no significant sex difference ( p = 0.46; Figure 2f ) or correlation with chlorpromazine equivalents ( r = 0.11, p = 0.36; Figure 2i ), while they were significantly correlated with imipramine equivalents ( r = 0.29, p = 0.034; Figure 2l ).
Notably, estriol use during radiotherapy showed a trend toward reducing subjective vaginal dryness (r=–0.297, p =0.053), highlighting its potential role in mitigating vaginal toxicity.
However, CLP-CBG mice showed a trend toward a faster heart rate compared to control CLP mice ( P = .053), with a significant treatment × time effect ( P = .006).
Univariate analysis revealed that none of the clinicopathological factors were significantly associated with PFS, although advanced clinical stage showed a trend toward poorer PFS (hazard ratio = 8.337, 95% confidence interval, 0.973–71.399, P = 0.053).
Post hoc analysis with Bonferroni correction revealed no significant difference between Sessions 1 and 2 ( p = 0.574), but accuracy in Session 3 showed a trend toward improvement compared with Sessions 1 ( p = 0.053) and 2 ( p = 0.081), although these did not reach the corrected significance threshold.
Patients more recently diagnosed with schizophrenia showed a trend toward lower relapse (10.5% versus 21.8%; p = 0.053), and significantly better improvement in psychotic symptoms as assessed by Positive and Negative Syndrome Scale [PANSS; mean ± standard deviation (SD): PANSS total score change −10.2 ± 2.0 versus −3.8 ± 0.9; p = 0.004] and Clinical Global Impressions, Severity Scale (CGI-S; mean ± SD: CGI-S score −0.5 ± 0.1 versus −0.2 ± 0.1; p = 0.002).
In this context, although not statistically significant, weight showed a trend ( p = 0.053) towards significance, probably due to the large representation of male subjects both in the recurrent group and in the whole series.
When comparing median distances from the electrodes to the center of the ampulla between both groups, the electrodes in the study group showed a trend toward closer positioning to the center of the ampulla ( p = 0.053).
In a subgroup that underwent open RH ( n = 33), adjuvant RT showed a trend toward improved RFS with borderline statistical significance (adjusted HR, 0.098; 95% CI, 0.009–1.027; p = 0.053).
Cortisol AUCi showed a trend for an association with GS in a buffer of 5000 m ( r = − 0.308, p = 0.053).
Intravenous agents (Cangrelor/GPi) showed a trend towards lower risk of intraprocedural stent occlusion compared to oral dAPT (adjusted odds ratio [aOR] 0.30, [95% CI, 0.09–1.01], P = .053), though this did not reach statistical significance.
The post‐COVID recovery phase demonstrated similar benefits (time ratio 1.25, 95% CI: 1.11–1.40, p < 0.001), while the COVID period showed a trend toward increased intervals that approached significance (time ratio 1.09, 95% CI: 1.00–1.18, p = 0.053).
Patients with lymphopenia during PBT showed a trend toward poorer progression-free survival ( P = .053) compared to those with maintained lymphocyte counts.
Body mass did not change after training (0.5%, 95% CI -1.5 to 0.79, ES=−0.223, p=0.499), however percentage of body fat showed a trend to decrease (−4.5%, 95% CI -0.03 to 3.71, ES=0.705, p=0.053).
This showed a trend‐level association with SIS ( B = −0.413, SE = 0.210, β = −0.217, p = 0.053), indicating that the association between Risk and SIS was strongest when Rescue values were low.
Kelp blades from the southernmost site in Puget Sound (Squaxin) demonstrated an increased α , or initial linear slope with irradiance ( figure 3f , F 1,16 = 11.37, p = 0.004), and a yield ( F v / F m ) that showed a trend to be greater than at Tatoosh Island ( F 1,16 = 4.37, p = 0.053).
For ELISA, the dementia group showed a trend of lower Aβ1-42/Aβ1-40 (0.051 ± 0.021 vs. 0.062 ± 0.022, p = 0.053) and higher t-Tau (594 ± 502 vs. 313 ± 145, p = 0.028) and p181Tau (81 ± 46 vs. 56 ± 22, p = 0.034) than the MCI group.
Weighted mode MR also showed a trend toward reduced risks of hip OA (OR = 0.89, 95% CI: 0.80–1.00, P = 0.053).
Correlation between CNS-BFS and FVC: The K-CSN-BFS total score was not significant but showed a trend correlation with FVC percentages using Spearman rank-order correlation coefficients (rho = −.376, P = .053). 3.3.3.